The company

Pushing the boundaries of RNAi and CRISPR technologies

Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics.

We are a high-tech business unlike any other with expertise in RNAi technologies critical for development of animal models that can pave the way we develop drugs, by pin-pointing potential toxicities and guiding the development of safer, more effective therapeutics.

We are revolutionizing the creation of animal models by synergzing RNAi and CRISPR/Cas9 technologies for development of mice, rats and higher organisms.